Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Ephrat Levy-Lahad"'
Autor:
David A. Zeevi, Sophie Kirshberg, Dina Kort, Sharon Zeligson, Aharon Peretz, Ephrat Levy-Lahad, Tal Dror, Gheona Altarescu, Yehuda Kling, Fouad Zahdeh, Tzvia Rosen, Reeval Segel, Daniel Backenroth, Efrat Burak, David Zangen, Shai Carmi
Publikováno v:
Genetics in Medicine. 21:1390-1399
To develop an economical, user-friendly, and accurate all-in-one next-generation sequencing (NGS)-based workflow for single-cell gene variant detection combined with comprehensive chromosome screening in a 24-hour workflow protocol. We subjected sing
Autor:
Sari Lieberman, Ariela Tomer, Avi Ben-Chetrit, Oded Olsha, Shalom Strano, Rachel Beeri, Sivan Koka, Hila Fridman, Karen Djemal, Itzhak Glick, Todd Zalut, Shlomo Segev, Miri Sklair, Bella Kaufman, Amnon Lahad, Aviad Raz, Ephrat Levy-Lahad
Publikováno v:
Genetics in Medicine. 19:754-762
Population screening of three common BRCA1/BRCA2 mutations in Ashkenazi Jews (AJ) apparently fulfills screening criteria. We compared streamlined BRCA screening via self-referral with proactive recruitment in medical settings.Unaffected AJ, age ≥25
Publikováno v:
Genetics in Medicine. 19:628-634
Population screening for BRCA1/BRCA2. mutations is being considered for Ashkenazi Jews (AJ) because 2.5% carry recurrent deleterious mutations and effective cancer prevention exists. This study aimed to provide a qualitative focus on perspectives of
Autor:
Sari Lieberman, Bella Kaufman, Aviad E. Raz, Ephrat Levy-Lahad, Itzhak Glick, Oded Olsha, Avi Ben-Chetrit, Karen Djemal, Miri Sklair, Ariela Tomer, Sivan Koka, Todd Zalut, Rachel Beeri, Shalom Strano, Hila Fridman, Shlomo Segev, Amnon Lahad
Publikováno v:
Genetics in Medicine. 22:672
Population screening of three common BRCA1/BRCA2 mutations in Ashkenazi Jews (AJ) apparently fulfills screening criteria. We compared streamlined BRCA screening via self-referral with proactive recruitment in medical settings. Unaffected AJ, age ≥2
Publikováno v:
Genetics in Medicine. 14:688-694
BRCA genes are associated with hereditary breast and ovarian cancers. Guidelines worldwide currently recommend BRCA genetic testing in asymptomatic individuals only if they belong to "high-risk" families. However, population screening for BRCA1/2 may